Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

magicmine/iStock via Getty Images
A lot has changed in my perception of Allakos (ALLK) over the 2 years that I have been covering them. The principal change has been the discovery that the market size of the eosinophilic diseases it targets was underestimated…

Click here to view the original article.